To the Editor:Fibroblast growth factor receptor(FGFR)fusion,although uncommon,represents an important target for cancer treatment,particularly for solid malignancies primarily treated with chemotherapy.Biliary tract c...To the Editor:Fibroblast growth factor receptor(FGFR)fusion,although uncommon,represents an important target for cancer treatment,particularly for solid malignancies primarily treated with chemotherapy.Biliary tract cancer(BTC)is a notable example.Although folinic acid,fluorouracil,and oxaliplatin(FOLFOX)was the standard second-line treatment for advanced BTC,the objective response rate(ORR)was only 5%.The advent of targeted therapies,such as pemigatinib,revolutionized the clinical response in this patient population.展开更多
基金The study was supported by grants from Jiangsu Province 333 High Level Talents Project,Beijing Xisike Clinical Oncology Research Foundation(No.Y-HR2019-0367)Beijing Science and Technology Innovation Medical Development Foundation(No.KC2021-JX-0186-124).
文摘To the Editor:Fibroblast growth factor receptor(FGFR)fusion,although uncommon,represents an important target for cancer treatment,particularly for solid malignancies primarily treated with chemotherapy.Biliary tract cancer(BTC)is a notable example.Although folinic acid,fluorouracil,and oxaliplatin(FOLFOX)was the standard second-line treatment for advanced BTC,the objective response rate(ORR)was only 5%.The advent of targeted therapies,such as pemigatinib,revolutionized the clinical response in this patient population.
